Online inquiry

IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13759MR)

This product GTTS-WQ13759MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets ANGPTL3 gene. The antibody can be applied in Hypertriglyceridemia&Homozygous familial hypercholesterolemia research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_014495.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 27329
UniProt ID Q9Y5C1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13759MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15734MR IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA VX-15
GTTS-WQ9324MR IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA INCAGN-01876
GTTS-WQ3161MR IVTScrip™ mRNA-Anti-O-antigen, AR-101(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AR-101
GTTS-WQ14475MR IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA RO-7105705
GTTS-WQ9611MR IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-63723283
GTTS-WQ2557MR IVTScrip™ mRNA-Anti-IGF1R, AMG 479(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 479
GTTS-WQ9483MR IVTScrip™ mRNA-Anti-C5AR1, IPH-5401(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA IPH-5401
GTTS-WQ9993MR IVTScrip™ mRNA-Anti-env, KD-247(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA KD-247
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW